SCHEMBL13611387

SCHEMBL13611387

Cc1c(Nc2ccc(I)cc2Cl)c(C(N)=O)nn(C)c1=O

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 16/20 0.41
MAP2K2 P36507 5/20 0.38
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
RAF1 P04049 1/20 0.35
PDGFRB P09619 1/20 0.35
CSNK2A2 P19784 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CSNK2A3 Q8NEV1 1/20 0.35
AURKC Q9UQB9 1/20 0.35
CAMK2A Q9UQM7 1/20 0.35
LMNA P02545 1/20 0.34
SYK P43405 1/20 0.34
CSF1R P07333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12021813 0.88 MAP2K1 (0.43) MAP2K1MAP2K2CSNK2A2
SCHEMBL388862 0.87 MAP2K1 (0.52) MAP2K1MAP2K2
SCHEMBL388771 0.85 MAP2K1 (0.49) MAP2K1MAP2K2CSNK2A2
SCHEMBL391769 0.82 KCNH2 (0.45) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL391768 0.82 KCNH2 (0.45) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL392151 0.79 MAP2K1 (0.50) MAP2K1MAP2K2
SCHEMBL392921 0.76 MAP2K1 (0.58) MAP2K1MAP2K2
SCHEMBL391635 0.76 MAP2K1 (0.53) MAP2K1MAP2K2
SCHEMBL1516515 0.75 MAP2K1 (0.53) MAP2K1MAP2K2
SCHEMBL391524 0.75 MAP2K1 (0.52) MAP2K1MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1967516-B1 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA INC (US) 2009-11-04 EP disclosed
EP-1967516-A1 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases Array Biopharma, Inc. (US) 2008-09-10 EP disclosed